Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

95.76 +0.06 (+0.06%)
Streaming Delayed Price Updated: 9:46 AM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,216
Open 96.00
Bid (Size) 95.72 (1)
Ask (Size) 95.84 (2)
Prev. Close 95.70
Today's Range 95.50 - 96.38
52wk Range 70.73 - 97.76
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
  If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
+7.16%
+7.16%
1 Month
+9.03%
+9.03%
3 Month
+20.56%
+20.56%
6 Month
+8.19%
+8.19%
1 Year
+23.56%
+23.56%

More News

Read More
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
Via Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Via Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Via Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Via Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Via Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
Biomarin Pharmaceutical Earnings Preview
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
Via Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.